We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-5.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$176M
AUM Growth
-$3.89M
(-2.2%)
Cap. Flow
+$11.2M
Cap. Flow
% of AUM
6.35%
Top 10 Holdings %
Top 10 Hldgs %
22.1%
Holding
256
New
24
Increased
39
Reduced
133
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.86M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$3.65M |
| 3 |
TSVT
2seventy bio
TSVT
|
+$3.13M |
| 4 |
uniQure
QURE
|
+$3.1M |
| 5 |
Embecta
EMBC
|
+$2.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdaptHealth
AHCO
|
+$3.44M |
| 2 |
Elanco Animal Health
ELAN
|
+$2.97M |
| 3 |
Centene
CNC
|
+$2.7M |
| 4 |
iShares MBS ETF
MBB
|
+$2.05M |
| 5 |
Lantheus
LNTH
|
+$1.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.71% |
| 2 | Real Estate | 10.29% |
| 3 | Financials | 3.55% |
| 4 | Technology | 3.29% |
| 5 | Energy | 2.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
126
DELISTED
Cymabay Therapeutics
CBAY
| $224K | 0.13% |
15,000
| – | – |
|
127
Johnson & Johnson
JNJ
$599B
| $222K | 0.13% |
1,426
-45
| -3% | -$7.42K |
|
128
Boston Scientific
BSX
$65.1B
| $221K | 0.13% |
4,193
-166
| -4% | -$8.71K |
|
129
PACCAR
PCAR
$65.4B
| $221K | 0.13% |
2,600
-342
| -12% | -$29.1K |
|
130
O'Reilly Automotive
ORLY
$70.1B
| $214K | 0.12% |
3,525
-135
| -4% | -$8.47K |
|
|
SAFE
131
Safehold
SAFE
$1.17B
| $213K | 0.12% |
11,972
| – | – |
|
132
Pultegroup
PHM
$23.5B
| $205K | 0.12% |
2,775
-367
| -12% | -$29.3K |
|
133
Occidental Petroleum
OXY
$54.9B
| $204K | 0.12% |
3,141
-414
| -12% | -$26K |
|
134
Jack Henry & Associates
JKHY
$10.9B
| $203K | 0.12% |
1,344
-53
| -4% | -$8.55K |
|
135
McDonald's
MCD
$190B
| $203K | 0.11% |
769
-27
| -3% | -$7.7K |
|
136
Chevron
CVX
$378B
| $202K | 0.11% |
1,195
-148
| -11% | -$23.9K |
|
137
Mondelez International
MDLZ
$77.4B
| $201K | 0.11% |
2,900
-99
| -3% | -$7.13K |
|
138
Monster Beverage
MNST
$93.4B
| $200K | 0.11% |
3,783
-149
| -4% | -$8.47K |
|
139
Genuine Parts
GPC
$16.8B
| $197K | 0.11% |
1,362
-53
| -4% | -$8.23K |
|
140
Delta Air Lines
DAL
$55.6B
| $193K | 0.11% |
5,212
-689
| -12% | -$29.9K |
|
141
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
$7.61B
| $192K | 0.11% |
4,674
-17
| -0.4% | -$702 |
|
142
FlexShares High Yield Value-Scored Bond Index Fund
HYGV
$1.1B
| $191K | 0.11% |
4,800
-38
| -0.8% | -$1.53K |
|
143
APA Corp
APA
$12.3B
| $190K | 0.11% |
4,632
-587
| -11% | -$24.2K |
|
144
State Street SPDR Bloomberg High Yield Bond ETF
JNK
$7.28B
| $190K | 0.11% |
2,103
-14
| -0.7% | -$1.28K |
|
145
iShares US & Intl High Yield Corp Bond ETF
GHYG
$185M
| $190K | 0.11% |
4,570
-15
| -0.3% | -$634 |
|
146
iShares Fallen Angels USD Bond ETF
FALN
$1.64B
| $189K | 0.11% |
7,637
-74
| -1% | -$1.87K |
|
147
Lamb Weston
LW
$6.43B
| $185K | 0.1% |
1,997
-74
| -4% | -$7.5K |
|
148
Bristol-Myers Squibb
BMY
$123B
| $183K | 0.1% |
3,153
-95
| -3% | -$5.82K |
|
149
Humana
HUM
$47.8B
| $182K | 0.1% |
374
-51
| -12% | -$24K |
|
150
J.M. Smucker
SJM
$12B
| $181K | 0.1% |
1,476
-48
| -3% | -$6.82K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, AlphaCentric Advisors held 256 positions worth $176M, down 2.2% from $180M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $11.2M of net new capital in Q3 2023, opening 24 new positions and adding to 39 existing holdings. Its largest new stake was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 60% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $1.9M trimmed.
- AlphaCentric Advisors's largest Q3 2023 buy was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
- AlphaCentric Advisors added most to Walgreens Boots Alliance in Q3 2023, an estimated $3.86M increase.
- AlphaCentric Advisors's biggest Q3 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $1.9M.
- AlphaCentric Advisors fully exited AdaptHealth in Q3 2023, selling an estimated $3.44M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $176M portfolio in Q3 2023.
- AlphaCentric Advisors opened 24 new positions and closed 21 in Q3 2023.
- AlphaCentric Advisors's portfolio value fell 2.2% quarter-over-quarter to $176M.
Based on AlphaCentric Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.